Abstract: This disclosure relates to generating interactive graphical visualisations of clinical and genetic data. A processor receives the clinical data indicative of observed phenotypes, accesses a database to determine associations of the observed phenotypes with disorders and accesses a second database to determine associations between the disorders and genetic properties. The processor then determines an association value for each combination of the observed phenotypes and the genetic properties based on a number of paths between them. The processor also generates a graphical user interface, comprising an arrangement of the association values and a user control element associated with the phenotypes and/or the genetic properties. Finally, upon detecting user interaction in relation to the user control element, the processor re-arranges the arrangement of the association values in the graphical user interface to reflect the detected user interaction.

Abstract: This disclosure relates to methods and systems for processing of sequencing data streams. The system receives sequences from a sequencer and stores them as data records on a database. The sequences are associated with a counter indicative of a number of times the associated sequence has been sequenced. The system progressively receives a further sequence as streaming data from the sequence. While receiving the further sequence, the system matches the streaming data against the stored sequences to determine a matching score. Upon the matching score exceeding a matching threshold for one of the multiple sequences in the database, the system selects the one of the sequences in the database based on the matching score and stores the further sequence on non-volatile memory where the counter value associated with the selected sequence is below a saturation threshold. The system also terminates the receiving where the counter value is above the saturation threshold.

Abstract: The present disclosure provides methods and reagents for the diagnosis, prognosis or the monitoring of breast cancer, including various subtypes of breast cancer including, for example, estrogen receptor (ER) negative breast cancer, ER positive breast cancer, triple negative breast cancer (TNBC) and other subtypes of breast cancer.

Abstract: The present disclosure provides an isolated, engineered or non-naturally occurring protein comprising an antibody light chain variable domain (VL) which may comprise at least one negatively charged amino acid positioned between residues 49 to 56 according to the numbering system of Kabat, the protein capable of binding specifically to an antigen.

Abstract: The present disclosure relates to an improved methodology for phenotyping and molecular characterisation of single cells using high-throughput and multiplexed targeted long-read single cell sequencing. In one particular example, the present disclosure relates to a methodology which combines targeted long-read sequencing with short-read based transcriptome profiling of barcoded single cell libraries generated by droplet-based partitioning for high throughput deep single cell profiling.

Abstract: The present disclosure relates to methods of generating antibodies with improved specificity and/or affinity for a target antigen, as well as B-cells and hybridomas expressing the antibodies and compositions comprising antibodies with improved specificity and/or affinity for the target antigen.

Abstract: This disclosure relates to generating interactive graphical visualisations of clinical and data. A processor calculates phenotype-to-phenotype similarity value indicative of a similarity between observed phenotypes and each phenotype in a set of stored phenotypes based on an ontology of phenotypes. The processor then determines an assignment of stored phenotypes to observed phenotypes based on the similarity values and further aggregates the similarity values into a set-to-set similarity value indicative of a similarity between the observed phenotypes and the set of stored phenotypes. The processor then repeats these steps to calculate a set-to-set similarity measure for each of the multiple sets. Finally, the processor selects one or more of the multiple sets based on the set-to-set similarity value and generates a graphical user interface comprising a graphical indication of the selected one or more of the multiple sets in relation to the multiple observed phenotypes.

Abstract: This disclosure relates to generating interactive graphical visualisations of clinical and genetic data. A processor receives the clinical data indicative of observed phenotypes, accesses a database to determine associations of the observed phenotypes with disorders and accesses a second database to determine associations between the disorders and genetic properties. The processor then determines an association value for each combination of the observed phenotypes and the genetic properties based on a number of paths between them. The processor also generates a graphical user interface, comprising an arrangement of the association values and a user control element associated with the phenotypes and/or the genetic properties. Finally, upon detecting user interaction in relation to the user control element, the processor re-arranges the arrangement of the association values in the graphical user interface to reflect the detected user interaction.

Abstract: The disclosure relates generally to methods and reagents for reducing or shutting down lactation in a non-human mammalian subject. In particular, the disclosure relates to a method of reducing or shutting down lactation in a non-human mammalian subject by administering to the subject by intramammary infusion an agent which activate the OAS2 signalling pathway or induce expression of OAS2. In some examples, the methods and reagents of the disclosure may be useful for the prevention of mastistis in a non-human mammalian subject, such as a dairy cow.

Abstract: This disclosure relates to methods and systems for processing of sequencing data streams. The system receives sequences from a sequencer and stores them as data records on a database. The sequences are associated with a counter indicative of a number of times the associated sequence has been sequenced. The system progressively receives a further sequence as streaming data from the sequence. While receiving the further sequence, the system matches the streaming data against the stored sequences to determine a matching score. Upon the matching score exceeding a matching threshold for one of the multiple sequences in the database, the system selects the one of the sequences in the database based on the matching score and stores the further sequence on non-volatile memory where the counter value associated with the selected sequence is below a saturation threshold. The system also terminates the receiving where the counter value is above the saturation threshold.

Abstract: This disclosure relates to RNA interference (RNAi) reagents for treatment of neuroblastoma, compositions comprising same, and use thereof to treat individuals suffering from neuroblastoma as a monotherapy or in combination with a chemotherapeutic agent. In particular, the present disclosure relates to microRNAs (miRNAs) which affect viability of neuroblastoma cells.

Abstract: This disclosure relates to a device for presenting whole genome sequence data. A file system stores a first file comprising short variant data and a second file comprising long variant data. A database stores variant data as data records. A display device displays a representation of variants. Finally, a processor is configured to create a data record in the database for each of the multiple short variants and identify for each of the short variant coordinates one of the multiple long variants. The processor then adds to the data record of that short variant a reference to the identified one of the multiple long variants. The processor also generates a user interface with a representation of the multiple short variants that comprise long variant data of the long variant according to the reference from the data record for each of the multiple short variants.

Abstract: The present disclosure relates to methods and reagents for treating or preventing metabolic disorders, including, but not limited to, type 2 diabetes, obesity, hyperglycaemia and other conditions associated with an abnormality of glucose metabolism.

Abstract: The present disclosure provides methods and reagents for the diagnosis, prognosis or the monitoring of breast cancer, including various subtypes of breast cancer including, for example, estrogen receptor (ER) negative breast cancer, ER positive breast cancer, triple negative breast cancer (TNBC) and other subtypes of breast cancer.

Abstract: The present disclosure provides an isolated, engineered or non-naturally occurring protein comprising an antibody light chain variable domain (VL) which may comprise at least one negatively charged amino acid positioned between residues 49 to 56 according to the numbering system of Kabat, the protein capable of binding specifically to an antigen.

Abstract: The present invention provides methods for diagnosis and monitoring the efficacy of treatment of a cancer. More particularly, the methods of the invention comprise detecting an enhanced degree of chromatin modification within Chromosome 2 of the human genome from about map position 2q14.1 to about map position 2q14.3 in a sample derived from a subject. The methods include detecting an enhanced level of methylation, or detecting an enhanced level of modification of a histone positioned within the chromatin within the region of about 2q14.1 to 2q14.3 of Chromosome 2. The methods also include detecting a modulated level of expression of a gene within the region of about 2q14.1 to 2q14.3 of Chromosome 2.

Abstract: The present invention provides a method for increasing metabolism and/or energy expenditure in a subject, e.g., to treat or prevent obesity and/or a related condition and/or the reduce adiposity, the method comprising increasing the level and/or activity of Hypoxia Induced Factor 1? (HIF-1?) in a cell, tissue or organ of the subject, thereby increasing metabolism in the subject. The present invention also provides a method for increasing metabolism in a subject, the method comprising administering an iron chelating agent to the subject, thereby increasing metabolism in the subject.

Abstract: The present disclosure generally relates to protein binding agents, such as protein kinase binding agents of general Formula (I). The protein binding agents may be provided attached to a solid support and may be used, for example, to detect the presence of a broad range of proteins in a sample. Methods of synthesizing the protein binding agents, and kits comprising the protein binding agents, are also disclosed.

Abstract: The present disclosure provides an isolated, engineered or non-naturally occurring protein comprising an antibody light chain variable domain (VL) which may comprise at least one negatively charged amino acid positioned between residues 49 to 56 according to the numbering system of Kabat, the protein capable of binding specifically to an antigen.

Abstract: The present invention disclosed a medical use of cucurbitane triterpenoids represented by the following formula and isolated from Momordica charantia L. of Cucurbitaceae family in the preparation of medications for prevention and treatment of diabetes and obesity. The above cucurbitane triterpenoids may be acted as a glucose uptake stimulator, an agonist for the translocation of glucose transporter 4 (GLUT4) to the cell membrane, and an activator of adenosine monophosphate-activated protein kinase (AMPK). They may have potential for the prevention and treatment of diabetes and obesity.